Navigating the 340B landscape in 2026 requires more than just clinical excellence; it demands a rigorous approach to provider enrollment services and regulatory maintenance. As drug manufacturers tighten the screws on contract pharmacy arrangements, your clinic’s Medicare enrollment and overall revenue cycle are on the line. If you think 340B is just a pharmacy department issue, you are overlooking a massive risk to your organization's professional credibility and financial stability.
The New Reality: Manufacturer Restrictions
The days of "set it and forget it" for 340B are over. As of February 2026, Eli Lilly has expanded its claims-level data requirements to include in-house dispenses. If you fail to submit this data via 340B ESP within the required 45–60 day window, you will lose 340B pricing. Novo Nordisk has followed suit, and nearly a dozen other manufacturers: including AstraZeneca and Sanofi: now enforce strict limits on the number of contract pharmacies you can utilize.
Recent data shows that 30% of covered entities are currently non-compliant with these mandates. This isn’t just a missed discount; it is a direct threat to your bottom line.
Audit Risks: Why OPAIS Is Your Biggest Weakness
When HRSA comes knocking, they aren’t looking at your patient care; they are looking at your paperwork. According to industry data from Pease Bell, industry analyses show a large share of adverse HRSA audit findings trace back to incorrect or incomplete OPAIS records. Common failures include:
- Lapsed contracts listed as active.
- Missing child sites that haven’t been properly enrolled.
- Stale contact information for authorizing officials.
- Outdated Medicare cost report references.
HRSA uses risk-based targeting. If your contract pharmacy setup is complex or your data is outdated, you are a primary target. A failed audit doesn't just mean paying back discounts; it can trigger a domino effect across your entire enrollment profile.
The Veracity Connection: 340B and Payer Enrollment
This is where most clinics get blindsided: 340B compliance violations can jeopardize your Medicare billing privileges. Significant 340B compliance violations can draw broader regulatory scrutiny, including from CMS, especially where Medicare billing and Medicaid duplicate discounts are implicated.
The integrity of your 340B program relies on the same operational rigor we apply to our provider enrollment services. Your OPAIS data must match your CAQH profile, your NPI/taxonomy must be active, and your PTAN must be in good standing. Clean data is the backbone of your revenue.
Protect Your Practice Now
The complexity of the HRSA manufacturer notices and the shifting legal landscape: such as recent federal court rulings reshaping how nondiscrimination and contract pharmacy restrictions are interpreted under 340B: means you cannot afford to be reactive.
You must:
- Audit your OPAIS records quarterly, not annually.
- Verify all contract pharmacy agreements are registered and current.
- Document your patient-definition policy to avoid diversion charges.
- Ensure every 340B script traces back to an eligible provider at a registered location.
Compliance is not a suggestion; it is a survival strategy. Incomplete enrollment data or a "close enough" approach to 340B will lead to denials, audits, and potentially a total revenue shutdown.
Looking for professional provider credentialing services in the USA?
👉 Check our main service page here: veracityeg.com
#340B #HRSA #FQHC #PharmacyAudit #HealthcareCompliance #MedicalBilling #ProviderEnrollment #RevenueCycle #CMS #Medicare #DrugPricing #HealthcareAdmin #ClinicalOperations #ContractPharmacy #OPAIS #HealthcareLaw #SafetyNet #MedicalPractice #ClinicManagement #AuditDefense #EliLilly #NovoNordisk #HealthcareFinance #VeracityGroup #Credentialing
